Given the therapeutic promise of GLP-1 and GIP in diabetes and obesity management, this study advances our understanding of incretin regulation, paving the way for potential incretin secretagogue therapies in the treatment of diabetes and obesity. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.